Breakthrough Presentations at ESGCT Annual Meeting
Asklepios BioPharmaceutical, Inc. (AskBio) is set to showcase its advancements in gene therapy at the upcoming European Society of Gene and Cell Therapy (ESGCT) 31st Annual Meeting. This event marks a significant opportunity for AskBio to share its progress in both clinical and pre-clinical settings concerning adeno-associated virus (AAV) therapies. The meeting will take place in Rome, bringing together experts and innovators in the field.
Highlights of Presentations
AskBio will feature an impressive lineup of 11 presentations, consisting of two oral sessions and nine poster sessions. These presentations underscore the company’s ongoing commitment to advancing its pioneering research and development initiatives. Notably, this year’s presentations tie into recent milestones in AskBio's clinical programs, such as the commencement of recruitment for the Phase 2 GenePHIT trial for AB-1002, an investigational gene therapy targeting congestive heart failure.
Oral Presentations
The oral presentations are designed to present new strategies in gene therapy, particularly the focus on treating central nervous system disorders. Noteworthy sessions will include:
- In Vivo Gene Therapy Strategies – Focus on CNS (EDU07) - This session will delve into innovative approaches for treating diseases that affect the central nervous system.
- Clinical Progress for AB-1005 (AAV2GDNF) - This presentation will provide insights into the developments for treating Parkinson’s disease, demonstrating AskBio's commitment to addressing severe neurological challenges.
Poster Sessions
In addition to oral presentations, AskBio will showcase a variety of research posters that include:
- Evaluation of Mutant Huntingtin Knockdown - This research investigates the effects of AAV-miHTT constructs in pre-clinical models of Huntington’s disease.
- Enhancing AAV Vector Manufacturing - This session focuses on advanced methods to optimize the production of AAV vectors, crucial for effective gene therapy.
- Characterization of rAAV Products - Presenters will discuss methods for improving the characterization of AAV products using high-throughput screening technologies.
Commitment to Innovation
Under the leadership of CEO Gustavo Pesquin, AskBio continues to reinforce its dedication to research and the development of next-generation therapies. The company employs a robust gene therapy platform, which includes its proprietary Pro10™ production process. This unique process enables the production of effective gene therapies while paving the way for advancements that have the potential to transform patient care for conditions like Huntington’s disease, cardiac dysfunction, and other severe conditions.
About AskBio
AskBio is wholly owned by Bayer AG and serves as a fully integrated gene therapy company. With various clinical programs in place aimed at addressing significant diseases across neuromuscular and metabolic conditions, the commitment to innovation and effective patient outcomes is at the forefront of its mission.
Frequently Asked Questions
What is the ESGCT Annual Meeting?
The ESGCT Annual Meeting is a significant event where scientists and industry leaders gather to share advancements and research in gene and cell therapy.
How many presentations will AskBio deliver?
AskBio will deliver a total of 11 presentations, including both oral and poster formats at the upcoming ESGCT Annual Meeting.
What are the main focus areas of AskBio's research?
AskBio focuses on developing gene therapies for neuromuscular, central nervous system, cardiovascular, and metabolic conditions, including significant diseases like Parkinson’s Disease and congestive heart failure.
Who is leading AskBio?
Gustavo Pesquin serves as the Chief Executive Officer of AskBio and leads the organization in its mission to develop cutting-edge therapies.
What is Pro10™?
Pro10™ is AskBio's proprietary cell line manufacturing process designed to optimize the production of gene therapies, significantly enhancing the efficiency and effectiveness of therapeutic development.
